Oncolys BioPharma, Inc.

Industry

  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing

Other Names/Subsidiaries

  • Oncolys USA
See more in Biomedtracker

Latest on Oncolys BioPharma, Inc.

Scrip

Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

 
• By Joseph Haas, Jung Won Shin, Brian Yang, and Ian Haydock

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Celltrion Teams With iProgen

Scrip

Deal Watch: Merck Digging Into Epigenetics With Proteros Partnership

 
• By Joseph Haas, John Davis, Ian Haydock, and Ying Huang

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Nov. 21 and Dec. 2.

Scrip

US venture Acucela looks east for $125m IPO

 
• By Ian Haydock

Acucela, a US venture specializing in ophthalmic disorders, is planning to raise up to $125m in an initial public offering in Tokyo to support the development and commercialization of its pipeline. Al

Scrip

Oncolys shares still ahead after $46m IPO

 
• By Ian Haydock

The Japanese venture Oncolys BioPharma has floated on the Mothers high-tech market of the Tokyo Stock Exchange, raising around JPY4.7bn ($46m) to develop its pipeline of drugs and diagnostics for canc